Jury Still Out On Screening For Thyroid Disease - AHRQ Draft Report
This article was originally published in The Gray Sheet
Executive Summary
The benefits and harms of screening for subclinical thyroid disease remain inadequately studied, according to a recent draft report from the Agency for Healthcare Research and Quality
You may also be interested in...
USPSTF Withholds Routine Thyroid Screening Blessing, Calls For More Data
Large, randomized trials are needed to determine the probability that treatment will enhance the quality of life for otherwise healthy patients with abnormal thyroid-stimulating hormone (TSH) levels, according to the U.S. Preventive Services Task Force
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.